Nevro Corp. (NYSE:NVRO) Q1 2024 Earnings Call Transcript

Justin Lin: Got it, helpful. Thank you.

Operator: And next we’ll go to Brad Bowers at Mizuho Securities.

Bradley Bowers: Hi, thanks for fitting me in. I just wanted to follow-up on one from Mizuho and on behalf of Anthony. Just wanted to go back to the Vyrsa strategy. It sounds like a lot of the work being done right now is on existing Nevro physicians and getting them trained, but it sounds like a longer term or medium to longer-term strategy is for Vyrsa to be used as kind of a door opening tool to get into practices where Nevro maybe is it the majority choice for SCS. So just wanted to hear when do you think you’ll be able to kind of switch the sales force to focus on new accounts and leading with Vyrsa SI and trying to take some market share back in the pain practices. Is that something that will be maybe a help for numbers this year? Is that something that maybe we should consider more of a next year item? Thank you.

Kevin Thornal: Yes, for sure. I mean, a lot of our sales reps have already taken advantage of the opportunity to have conversations with physicians that maybe had told them now over a period of time, and now they have something new to talk about. So we’re excited about those physicians in the queue for training. Obviously, the results we were talking about today were a lot towards Q1. But as we’re already into Q2, the mix shift to physicians attending our trainings are including all comers. So Nevro physicians that have put SCS and Nevro devices in for a decade and some that are implanters of other devices for SCS and also learning the Nevro1 device. So we’ll do a lot of both.

Bradley Bowers: Thank you.

Kevin Thornal: Yes, thank you.

Operator: And that does conclude our Q&A session and today’s conference call. We thank you for your participation. You may now disconnect.